首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献，搜索用时 156 毫秒
1.
The role of decreased luteal activity in embryonic loss after induced endotoxemia was studied in mares 21 to 35 days pregnant. Fourteen pregnant mares were treated daily with 44 mg of altrenogest to compensate for the loss of endogenous progesterone secretion caused by prostaglandin F2 alpha (PGF2 alpha) synthesis and release following intravenous administration of Salmonella typhimurium endotoxin. Altrenogest was administered daily from the day of endotoxin injection until day 40 of gestation (group 1; n = 7), until day 70 (group 2; n = 5), or until day 50 (group 3; n = 2). In all mares, secretion of PGF2 alpha, as determined by the plasma 15-keto-13,14-dihydro-PGF2 alpha concentrations, followed a biphasic pattern, with an initial peak at 30 minutes followed by a second, larger peak at 105 minutes after endotoxin injection. Plasma progesterone concentrations decreased in all mares to values less than 1 ng/ml within 24 hours after endotoxin injection. In group 1, progesterone concentrations for all mares were less than 1 ng/ml until the final day of altrenogest treatment. In 6 of 7 mares in group 1, the fetuses died within 4 days after the end of treatment, with progesterone concentrations less than 1 ng/ml at that time. In the mare that remained pregnant after the end of treatment, plasma progesterone concentration was 1.6 ng/ml on day 41 and increased to 4.4 ng/ml on day 44. In group 2, all mares remained pregnant, even though plasma progesterone concentrations were less than 1 ng/ml in 4 of 5 mares from the day after endotoxin injection until after the end of altrenogest treatment.(ABSTRACT TRUNCATED AT 250 WORDS)  相似文献   

2.
Objective: To compare the effect of negative pressure wound therapy (NPWT) with standard‐of‐care management on healing of acute open wounds in dogs. Study Design: Prospective, controlled, experimental study. Animals: Adult dogs (n=10). Methods: Full‐thickness 4 cm × 2 cm wounds were surgically created on each antebrachium and in each dog were randomized to receive either NPWT or standard wound dressings (CON) for 21 days. Dressing changes and wound evaluations were made at 8 time points. First appearance of granulation tissue, smoothness of granulation tissue, exuberance, percent epithelialization, and percent contraction were compared. Biopsies for histopathology were taken, and histologic scores determined, at 5 time points, and aerobic bacterial wound cultures performed at 2 time points. Results: Granulation tissue appeared significantly earlier, and was smoother and less exuberant in NPWT wounds compared with CON wounds. Percent contraction in NPWT wounds was less than CON wounds after Day 7. Percent epithelialization in NPWT wounds was less than CON wounds on Days 11, 16, 18, and 21. Histologic scores for acute inflammation were higher in NPWT on Day 3, and lower on Day 7, than CON wounds. Bacterial load was higher in NPWT on Day 7. Conclusion: NPWT accelerated appearance of smooth, nonexuberant granulation tissue; however, prolonged use of NPWT impaired wound contraction and epithelialization.  相似文献   

3.
The effects of two concentrations of triiodothyronine (T3; 0.01 and 1,000 nM) on the osteogenic and chondrogenic differentiation abilities of equine adipose-derived mesenchymal stem cells (AD-MSCs) were evaluated. The osteogenic study evaluated the effect of T3 using alkaline phosphatase activity (ALP) assay; cell viability and density; and formation of mineralized nodules at Days 7, 14, and 21 in culture. The chondrogenic study tested the effect of T3 through ALP assay, mitochondrial metabolism, cell density, and periodic acid–Schiff-positive (PAS+) matrix percentage at Days 7 and 14. In both experiments, analysis of variance was used to compare averages through the Student–Newman–Keuls test. In the osteogenic study, no differences in any variable were detected between groups at Day 7. At Day 14, 0.01 nM T3 reduced cell density and the number of mineralized nodules despite the increase in ALP activity and mitochondrial metabolism (P < .05). ALP activity increased at 1,000 nM T3 concentration (P < .05). At Day 21, 0.01 nM T3 treatment increased ALP activity compared with control treatment (P < .05). At 1,000 nM concentration, T3 reduced mitochondrial metabolism and cell density (P < .05). In the chondrogenic study, the two T3 concentrations increased cell density compared with control treatment at Day 7. At Day 14, higher T3 concentration reduced mitochondrial metabolism, ALP activity, cell density, and PAS+ chondrogenic matrix percentage compared with control treatment (P < .05). Thus, T3 addition to equine AD-MSC cultures has no enhancement effect on osteogenic or chondrogenic differentiation and may, in fact, negatively affect cell density and matrix synthesis depending on hormone concentration and culture time.  相似文献   

4.
AIM: To determine the concentration of the anti-theilerial drug buparvaquone in the milk and tissue of dairy cattle following treatment with two different formulations, and to assess the effect of clinical theileriosis on the concentration of buparvaquone in milk.

METHODS: Healthy lactating dairy cows (n=25) were injected once (Day 0) I/M with 2.5?mg/kg of one of two formulations of buparvaquone (Butalex; n=12 or Bupaject; n=13). Milk samples were collected from all cows daily until Day 35. Five cows were slaughtered on each of Days 56, 119, 147, 203 and 328, and samples of liver, muscle and injection site tissue collected. Milk samples were also collected from cows (n=14) clinically affected with theileriosis for up to 21 days after treatment with buparvaquone. Milk and tissue samples were analysed by liquid chromatography-mass spectrometry; limits of detection (LOD) were 0.00018?mg/kg for muscle and 0.00023?mg/L for milk. Concentrations of buparvaquone in milk and tissues were log10-transformed for analysis using multivariate models.

RESULTS: In healthy cows, concentrations of buparvaquone in milk declined with time post-treatment (p<0.001), but were above the LOD in 11 of 25 cows at Day 35. Concentration in milk was higher one day after treatment in cows treated with Butalex than in cows treated with Bupaject, but not different thereafter (p=0.007). Concentrations of buparvaquone in muscle were below the LOD for four of five animals at Day 119 and for all animals by Day 147, but were above the LOD at the injection site of one cow, and in the liver of three cows at Day 328. Tissue concentrations did not differ with formulation nor was there a formulation by time interaction (p>0.3).

Concentrations of buparvaquone in the milk of clinically affected animals were not different from those of healthy animals at 1 and 21 days post-treatment (p=0.72). Between 21 and 25 days post-treatment concentrations were below the LOD in 9/14 milk samples from clinically affected cows.

CONCLUSIONS: Detectable concentrations of buparvaquone were found in the milk of some cows for at least 35 days and in the liver and injection site of some cows until at least 328 days after injection. There were no biologically meaningful differences in milk or tissue concentrations between the formulations, or in the milk concentrations for cows that were clinically affected compared with those that were healthy at the time of treatment.  相似文献   

5.
Synchronization of estrus (SE) in mares has been achieved, but not of ovulation (SO). Progestins followed by PGF2a are useful for SE only. In the two studies reviewed here, SE and SO were attempted by using CIDR-B, an intravaginal (itv) progesterone (1.9 g) releasing device, alone (study 1) or accompanied by estradiol (10 mg) given also itv (study 2). In both studies, Ovuplant™ (OT), an implant containing 2.1 mg of the GnRH analog deslorelin was used for the control of ovulation. Eighty cycling Hanoverian mares, 40 each in studies 1 and 2, received CIDR-B itv for 12 days, with PGF2a given once at CIDR-B removal. In study 1, 15 mares each received OT when the lead follicle had reached 40 mm (A) or on Day 3 of estrus (B); 10 controls received no OT (C). In study 2, E2 was used in addition on Day 0 (CIDR-B insertion) (10 mares; group II), or on Days 0 and 7 (10; group III) or not (20; groups I and IV). Mares in groups I to III received OT as in study 1 (A); group IV (10) remained untreated. Ovaries were examined and blood samples were taken in studies 1 and 2 from all mares in 1, 2 or 4-day intervals, respectively, and concentrations of FSH, LH, progesterone and estradiol were determined by RIA. In study 1, CIDR-B treatment achieved SE, but not SO as shown by a wide spread of days on which follicles were reaching 40 mm; OT treatment assured ovulations in 48 hours in 93.3% of treated mares vs. 44.4% in controls (P<0.05. In study 2, SE was achieved and SO, but only when estradiol was given once (itv) on Day 0 (group II) but not twice on Days 0 and 7 (group III). In both studies, CIDR-B prevented estrus but stimulated follicle growth: 8 mares in study 1 ovulated with CIDR-Bs in place and 2 in trial 2, respectively. Only when estradiol was used together with CIDR-B, follicle growth was retarded (group II) or suppressed (group III: P<0.05 vs. groups I and IV). The pregnancy rate in study 2 from a single breeding at the first estrus was 52.8% with no significant differences between groups. FSH rose until Day 4 or 8 and had dropped sharply at Day 12; after CIDR-B removal FSH rose most quickly in group II, study 2. LH declined slightly until Day 12 and rose thereafter, reaching peak levels by Day 18 or 20, respectively. In both studies, estradiol had dropped slightly by Day 4 but increase steadily thereafter until ovulation had occurred. Preovulatory rise and postovulatory drop was seen earlier in group II, study 2. Values for progesterone had risen uniformly by Day 4, had declined slowly by Day 12 and precipitously in response to PGF2a by Day 14. Treatment of cyclic mares with CIDR-B for 12 days, followed by PGF2a at the day of CIDR-B removal and by Ovuplant™ a deslorelin implant when a follicle had reached 40 mm, resulted in synchronization of estrus. Adding to this scheme a single dose of estradiol (10 mg, intravaginal) on Day 0 resulted also in synchronization of ovulation.  相似文献   

6.
Mechanism of macrophage activation by chitin derivatives   总被引：4，自引：0，他引：4  
In order to analyze the detailed mechanisms responsible for macrophage activation by chitin derivatives, resident peritoneal macrophages were prepared and stimulated with chitin, chitosan and low-molecular weight chitosan. Our findings were as follows: (i) chitosan induced apoptosis of peritoneal macrophages, but this did not occur when chitin or water soluble low-molecular weight chitosan were used; (ii) chitosan treatment induced activation markers, such as the major histocompatibility complex (MHC) class I, class II, Fc receptors, transferrin receptor, mannose receptor, Fas, and macrophage inflammatory protein (MIP)-2, whereas chitin and low molecular weight soluble chitosan induced only the expression of MHC class I and II molecules; (iii) apoptosis induced by chitosan was mediated by the Fas signaling pathway, in response to phagocytosis via the mannose receptor. We conclude that since chitosan activates macrophages, this may be the mechanism by which it accelerates wound healing.  相似文献   

7.
防治奶牛乳房炎中药复方的抗炎作用及毒性作用研究   总被引：2，自引：1，他引：2  
本试验采用小鼠二甲苯性耳肿胀法、大鼠羧甲基纤维素囊中白细胞游出法和棉球诱发小鼠肉芽组织增生法研究了防治奶牛乳房炎中药复方1、2的抗炎作用;采用改进Karber法,以半致死量(LD50)为评价急性毒性强度的指标,研究了复方1、2的急性毒性作用。试验结果表明:复方1对二甲苯致小鼠耳廓的肿胀抑制率为18.84%、14.77%和9.85%,复方2的肿胀抑制率为16.80%、14.48%和7.41%;复方1、2对大鼠羧甲基纤维素囊中白细胞游出均有明显的抑制作用;复方1对小鼠肉芽组织的增生抑制率为27.53%、20.32%和13.12%,复方2的增生抑制率为29.34%、21.43%和12.58%,说明复方1、2对急慢性炎症各个时期均有较强的抗炎作用,且复方1抗炎效果优于复方2。中药复方1、2提取液经小鼠腹腔给药的LD50分别为6523.79mg/kg、22861.25mg/kg,复方1、2提取液的LD50的95%可信限分别为5513.91￣7718.63mg/kg、20641.44￣25319.78mg/kg,说明复方1、2属于实际无毒物质,可以应用于进一步临床试验研究。  相似文献   

8.
This study evaluated the pregnancy rates following either a controlled internal drug release (CIDR)-based timed artificial insemination (TAI) or an embryo transfer (TET) protocol compared with that following a single PGF(2alpha) injection and AI after estrus (AIE) in lactating repeat breeder dairy cows. Fifty-three lactating dairy cows diagnosed as repeat breeders were used in this study and were randomly assigned to the following three treatments. (1) Cows, at random stages of the estrous cycle, received a CIDR device and 2 mg estradiol benzoate (EB; Day 0), a 25 mg PGF(2) (alpha) injection at the time of CIDR removal on Day 7 and a 1 mg EB injection on Day 8. The cows then received TAI 30 h (Day 9) after the second EB injection using dairy semen (TAI group, n=13). (2) Cows, at random stages of the estrous cycle, received the same hormonal treatments as in the TAI group. The cows then received TET on Day 16 using frozen-thawed blastocysts or morula embryos collected from Korean native cattle donors (TET group, n=13). (3) Cows, at the luteal phase, received a 25 mg injection of PGF(2alpha) and AIE using dairy semen (control group, n=27). The ovaries of the cows in the TET group were examined by transrectal ultrasonography to determine ovulation of the preovulatory follicles, and blood samples were collected for serum progesterone (P4) analysis. The pregnancy rate was significantly higher in the TET group (53.8%) than in the control (18.5%) or TAI (7.7%) groups (P<0.05). The ultrasonographic observations demonstrated that all the cows in the TET group ovulated the preovulatory follicles and concomitantly formed new corpora lutea. Accordingly, the mean serum P4 concentration remained constant between Day 0 and Day 7 of the luteal phase, decreased dramatically on Day 8 (P<0.01) and subsequently increased by Day 16 (P<0.01). These data suggest that the CIDR-based TET protocol can be used to effectively increase the pregnancy rate in lactating repeat breeder dairy cows.  相似文献   

9.
AIM: To determine the changes in concentrations of fluorine (F) in serum and bone of young sheep given a high intake of F, as F in soil, followed by a low intake of F, to simulate the varying intakes experienced by grazing sheep. METHODS: Sixty autumn-born, weaned, mixed-sex lambs were randomly divided into two groups (n=30). One group (Control) was fed a low-F (12 mg/kg dry matter; DM) lucerne/ grain diet for 345 days, while the other group (High soil-F) was fed a high-F (224 mg/kg DM) lucerne/grain diet containing 10% soil for 94 days and then a low-F diet for a further 251 days. Blood samples were collected on Days 1, 32, 94, 108, 153, 214, 280 and 345, to determine concentrations of F in serum. Groups of five or six animals from each group were killed on Days 1, 94, 153, 214, 280 and 345, to collect radii and humeri for determination of F content. The sheep were weighed at about 6-8-weekly intervals. RESULTS: Initial liveweight of the sheep was 22.1 (standard error (SE) 1.12) kg and the mean liveweight gains were 270 (SE 22.1) and 170 (SE 12.4) g/day from Days 1 to 94 and 95 to 330, respectively. The mean initial (Day 1) concentration of F in serum was 0.03 (SE 0.005) mg/L, and this changed very little for animals on the low-F diet. In sheep on the high soil-F diet, the concentration of F in serum reached 0.38 (SE 0.021) mg/L at Day 94 but after being placed on the low-F diet concentrations decreased to 0.04 (SE 0.006) mg/L after 14 days (Day 108) and then remained at about this low level for the remainder of the duration of the study. The mean concentrations of F in the humerus and radius of the lambs at Day 1 were 161 (SE 19.4) and 159 (SE 20.4) mg/kg DM, respectively, which increased to 2,784 (SE 80.6) and 1,805 (SE 51.5) mg/kg DM, respectively, at Day 94 in lambs fed the high soil-F diet, then decreased to 1,075 (SE 58.1) and 1,064 (SE 61.6) mg/kg DM at Day 153, and then progressively increased to 1,669 (SE 57.7) and 1,312 (SE 30.8) mg/kg DM at Day 345. CONCLUSIONS: The ingestion of F in soil by sheep markedly increased their concentrations of F in serum and bone, but when the soil was removed and they were fed a low-F diet, concentrations of F in serum decreased to baseline levels within 14 days while concentrations in the bone only decreased to 60-70% of the peak concentration, indicating that some of the F in bone was remobilised.  相似文献   

10.
甲壳素和壳聚糖营养研究进展   总被引：8，自引：0，他引：8  
甲壳素、壳聚糖是一种新型绿色饲料添加剂,具有降脂、抗菌抑菌和免疫调节等多种生物学活性,本文综述了甲壳素、壳聚糖的生理生化功能以及在畜禽日粮中添加的生物学效应,为进一步促进其开发利用提供理论依据。  相似文献   

11.
1. The effect of dietary chitosan on fat deposition and lipase activity in the small intestinal contents was investigated in broiler chickens fed an adequate or high metabolisable energy (ME) diet. 2. Male broiler chickens at 14 d old were fed on the adequate or high ME diet supplemented with 0 or 50 g/kg chitosan, which has a low viscosity, for 3 weeks. 3. Dietary chitosan did not affect food intake, body weight gain or food efficiency in either dietary ME groups. 4. Dietary chitosan reduced the excessive abdominal fat deposition induced by the high ME diet. 5. Dietary chitosan increased the weight of intestinal contents irrespective of dietary ME concentration. 6. Dietary chitosan decreased the lipase activity per g of small intestinal contents. 7. These results suggest that dietary chitosan with low viscosity decreases lipase activity and fat absorption in the small intestine, consequently resulting in a reduction of fat deposition in broiler chickens. 8. It was concluded that dietary chitosan with low viscosity can decrease body fat deposition without reducing food intake and body weight gain in broiler chickens.  相似文献   

12.
Spinosad is a novel mode-of-action insecticide produced from a family of natural products derived from fermentation of the actinomycete, Saccharopolyspora spinosa. Separate studies were undertaken to determine the minimum effective dose of spinosad given orally for the treatment of experimentally induced flea infestations (Ctenocephalides felis) on dogs, and to assess any potential impacts of feeding canned or dry food at the time of dosing. Both were randomized block (blocked by gender and pre-treatment flea counts), blinded parallel-arm studies, with dogs selected on health and ability to maintain pre-treatment flea populations. For dose selection, 48 dogs were allocated among six groups (8 dogs/group; 4 males, 4 females): placebo-treated negative control, spinosad in gelatin capsules at 15, 20, 30 and 40 mg/kg administered per os; and topical imidacloprid (10 mg/kg) as a positive control. Placebo and spinosad treatments were administered on Days 0, 30 and 60, imidacloprid only on Day 0. In a second study to assess the impact of food type at the time of dosing, three groups were formed: placebo-treated control (8 dogs; 4 males, 4 females), spinosad (30 mg/kg) administered with canned food (8 male dogs, 8 females); and spinosad (30 mg/kg) with dry food (8 males, 8 females). Treatments were administered on Days 0 and 30. To assess post-treatment persistent efficacy, flea infestations were repeated at regular post-treatment intervals, beginning on Day 5 through Day 89 in the dose selection study and Day 58 in the impact of food type and dosing study. Flea counts were performed 48 h post-infestation by study personnel who were blinded to treatments. In the dose selection study, compared to geometric mean live flea counts in the control group, each spinosad dose was highly effective (99.8–100%) at 7, 14 and 21 days after treatment. Only the 30 and 40 mg/kg doses maintained high efficacy (97.2–100%) until 30 days after treatment, with no difference between the two. Imidacloprid was highly effective at Day 30, with significant difference only from the 15 mg/kg spinosad group. Because there was no significant difference between the higher spinosad rates, 30 mg/kg was selected as the optimal minimum effective dose. In the second study, spinosad was highly effective at all post-treatment flea counts (98–100%). Taken together, these studies demonstrate that repeated monthly oral treatments with spinosad at 30 mg/kg provide sustained control of C. felis on dogs. There were no treatment-related adverse events in either study, indicating that spinosad has potential to be used monthly as a safe and effective flea adulticide, providing sustained activity that matches that of currently used topical products.  相似文献   

13.
There is a need for a safe, effective and practical method of oestrus suppression in the mare. The aim of this study was to monitor ovarian activity in mares exposed to either 9.4 or 28.2 mg deslorelin acetate, a GnRH agonist, in the form of a sustained-release implant. Following oestrus synchronisation, mares were randomly assigned to one of three groups (n = 4 per group) and administered either one (Des1 group; 9.4 mg) or three (Des3 group; 28.2 mg) implants of deslorelin acetate (Suprelorin-12, Virbac Australia) or one blank implant (Control group; Virbac Australia). Mares underwent weekly blood sampling for 12 weeks following implant placement (Day 0–Day 84), with transrectal palpation and ultrasonography of the reproductive tract at all sampling timepoints except Days 56, 70 and 77. All mares showed baseline serum progesterone concentrations (SPC; ≤1.3 nmol/L or 0.4 ng/ml) on Day 0. Cycling Control mares showed typical oestrous cyclicity characterised by peaks and troughs in SPC over time. Four of eight treated mares demonstrated a sustained elevation in SPC after the initial ovulation after implant placement; SPC declined to baseline levels (Des1 group; 2 mares) or remained elevated (Des3 group; 2 mares) at the final sampling timepoint on Day 84. Oestrous cyclicity was erratic in three of the remaining four treated mares. In total, 87.5% (7 of 8) of treated mares showed atypical oestrous cyclicity after implant placement. These results suggest that deslorelin acetate disrupts oestrous cyclicity in the mare, which warrants further research.  相似文献   

14.
A novel spot-on formulation containing metaflumizone and amitraz (ProMeris/ProMeris Duo for Dogs, Fort Dodge Animal Health, Overland Park, KS) was evaluated in a laboratory study to determine the appropriate dose for efficacy against fleas and ticks on dogs for 1 month. Thirty-six Beagles were randomly allocated to six equal groups and individually housed. One group remained nontreated. Another was treated with a placebo formulation (solvents with no active ingredients). Three groups of dogs were treated topically with the metaflumizone plus amitraz formulation (150mg of each of metaflumizone and amitraz/ml), at volumes providing doses of 10, 20 and 40mgeachactive/kg. The final group was treated with a commercial spot-on providing 6.7mgfipronil/kg. All treatments were applied to the skin at a single spot between the scapulae on Day 0. Dogs were infested with 50 adult brown dog ticks (Rhipicephalus sanguineus) on each of Days -2, 5, 12, 19, 26, 33 and 40, and with 100 cat fleas (Ctenocephalides felis felis) on Days -1, 6, 13, 20, 27, 34 and 41. Dogs were examined and parasites "finger counted" on Day 1 to estimate knock down efficacy, and all animals were comb counted to determine the numbers of viable fleas and ticks on Days 7, 14, 21, 28, 35 and 42. There were no significant differences in parasite counts between the nontreated control and the placebo-treated control groups for either fleas or ticks (P>0.05) except for very slight reductions on Day 7 for fleas and Day 14 for ticks, demonstrating that the formulation excipients had no activity. The qualitative finger counts on Day 1 indicated that all of the insecticidal treatments resulted in a noticeable reduction in flea and tick numbers within 1 day of treatment. All of the metaflumizone and amitraz treatments and fipronil resulted in significantly lower flea and tick numbers relative to nontreated controls on all posttreatment count days (P<0.05). For the metaflumizone plus amitraz treatments, mean flea and tick counts for the 10mg/kg dose were significantly higher than those for the 20mg/kg dose (P<0.05) from Day 21 on. There was no significant advantage provided by the 40mg/kg dose over the 20mg dose throughout the entire study (P>0.05). The two higher metaflumizone plus amitraz doses provided >95% control of fleas and >90% control of ticks for at least 35 days after treatment, and this level of control was similar to that of the commercial fipronil product. The 20mg/kg dose was selected as the minimum commercial dose rate to provide effective flea and tick control for at least 1 month following a single treatment.  相似文献   

15.
We examined the relations between plasma insulin-like growth factor (IGF) -I concentrations during treatment with CIDR-based or Ovsynch protocol for timed AI and conception and plasma steroid concentrations in early postpartum Japanese Black beef cows. Cows in the control group (Ovsynch; n = 21) underwent Ovsynch protocol (GnRH analogue on Day 0, PGF(2alpha) analogue on Day 7, and GnRH analogue on Day 9), with AI on Day 10, approximately 20 h after the second GnRH treatment. Cows in the Ovsynch+CIDR group (n = 22) received Ovsynch protocol plus a CIDR for 7 days (starting on Day 0). Cows in the further treatment group (EB+CIDR+GnRH; n = 22) received 2 mg of estradiol benzoate (EB) on Day 0 in lieu of the first GnRH treatment, followed by the same treatment as in the Ovsynch+CIDR protocol. Plasma IGF-I concentrations were determined on Days -7, 0, 7, 9 and 17. Conception rates were improved in the CIDR-combined groups (both CIDR-treated groups were combined) relative to Ovsynch group (P < 0.05) for cows with low IGF-I concentrations (<1,000 ng/ml) on Days -7, 0, and 7, but improved conception rate produced by the CIDR-based protocols did not occur in cows with a high IGF-I concentration (> or =1,000 ng/ml). Plasma estradiol-17beta concentrations increased from Day 0 to 7 (P < 0.05) and were unchanged from Day 7 to 9 in the Ovsynch group with low IGF-I concentrations on Day 0, while they were unchanged from Day 0 to 7 and increased from Day 7 to 9 (P < 0.05) in the Ovsynch group with high IGF-I concentrations on Day 0 and in the CIDR-combined group. Plasma progesterone concentrations in the Ovsynch group with low IGF-I concentrations on Day 0 were higher on Day 14 than in the Ovsynch group with high IGF-I concentrations on Day 0 and in the CIDR-combined group (P < 0.05). In conclusion, CIDR-based protocols may improve conception relative to Ovsynch in early postpartum beef cows with lower plasma IGF-I concentrations at the start of the protocols. This improvement is probably due to prevention of premature increases of estradiol-17beta and progesterone concentrations, which occurred in cows with low IGF-I concentrations treated with Ovsynch, by the CIDR treatment.  相似文献   

16.
Recurrent airway obstruction (RAO) or heaves is a manifestation of a hypersensitivity to dust, moulds, and spores in the environment of a susceptible horse. Although in the majority of RAO-affected horses, clinical remission can be achieved by keeping horses at pasture to reduce their allergen exposure, this often is not practicable. For this reason, we investigated if changing the environment of a single stall in a 4 stall stable was sufficient to improve lung function and reduce inflammation in RAO-affected horses. In addition, we determined if addition of oral prednisone provided additional benefit. Twelve RAO-susceptible horses were stabled, fed hay, and bedded on straw until they developed airway obstruction. At this point, bedding was changed to wood shavings and they were fed a pelleted diet for 2 weeks. Lung function was measured and bronchoalveolar lavage was performed before and 3, 7, and 14 days after environmental modification. In a crossover design, horses were treated for the 14 days with prednisone tablets (2.2 mg/kg bwt, q. 24 h). Horses then returned to pasture for 30 days. Airway obstruction was greatest before environmental modification. Significant improvement in lung function occurred within 3 days of the change in environment and continued to Day 7. Airway function was best after 30 days at pasture. The clinical response achieved by environmental modification was not significantly improved by addition of oral prednisone. The total number of cells, total neutrophils, and percent neutrophils was greatest before environmental modification. In the absence of prednisone, total and percent neutrophils did not decrease until Day 14 and total cell number until 30 days at pasture. In the presence of prednisone, total cells and total and percent neutrophils decreased by Day 3 and again at pasture. The fact that lung function can be improved within 3 days by environmental management alone emphasises the need for allergen reduction as the cornerstone of treatment of RAO. Although prednisone induced a more rapid reduction in airway inflammation, this was not associated with a more rapid improvement in airway function.  相似文献   

17.
Field efficacy of moxidectin, a macrocyclic lactone endectocide, was evaluated in cattle naturally infested with Psoroptes ovis. Three groups of six animals were used based on parasitological and clinical status. Group 1 animals received one subcutaneous injection of injectable moxidectin at 0.2 mg kg-1 body weight; Group 2 animals received topically one dose of 0.5 mg kg-1 body weight of pour-on moxidectin; Group 3 individuals remained untreated as controls. Efficacy was assessed by (a) taking skin samples from each animal on Days -4, 14, 28, 42 and 56 post-treatment (PT) and observing numbers of viable mite stages and species and (b) clinical examination of animals on Days 14, 28, 42 and 56 with the percentage of affected body surface calculated for each animal on Days -4, 28 and 56. Both formulations gave 100% efficacy as no live mites were found in Groups 1 or 2, 14, 28 and 56 days after treatment. Clinical indices showed a sharp decrease in the affected body surface area from a mean of 5.48% and 6.1% on Day -4 in Groups 1 and 2, respectively, to 0% in both groups on Days 28 and 56 PT. All untreated animals remained positive until Day 28. The clinical condition of the controls worsened rapidly during the experiment (mean clinical index: 2.87% and 13.05% on Days -4 and 28, respectively) and they were given an emergency treatment on Day 28. No side-effects were observed with either formulation.(ABSTRACT TRUNCATED AT 250 WORDS)  相似文献   

18.
Objective: To determine the effect of storage on ammonia concentration in canine packed red blood cell (pRBC) units.
Design: In vitro and in vivo study.
Setting: University Veterinary Teaching Hospital.
Interventions: Ammonia concentration was measured in 7 units of canine pRBC prepared in citrate-phosphate-dextrose (CPD) and Adsola on Days 1 and 35 of storage. Ammonia was measured in 4 additional units of canine pRBC on Days 0, 7, 14, 21, 28, and 35. Plasma ammonia was also determined in 5 anemic dogs receiving pRBC.
Measurements and Main Results: Ammonia concentration increased from 73 ± 15 mmol/L (mean ± SD) on Day 1 to 800 ± 275 mmpl/L on Day (p<0.001). When measured every 7 days in 4 units of canine pRBC, ammonia concentration increased from 23 ± 8 mmol/L on Day 0 to 179 ± 13 mmol/L (Day 7), 276 ± 56 mmol/L (Day 14). 383 ± 47 mmol/L (Day21), 466 ± 30 mmol/L (Day 28), and 562 ± 27 mmol/L (Day 35) (p<0.05 for all comparisons). In a preliminary study, plasma ammonia concentration measured in blood samples from 5 anemic dogs without primary liver disease immediately before and after transfusion with 5–10 ml/kg of stored pRBC remained in the normal reference range.
Conclusions: The ammonia concentration in stored canine pRBC increased markedly with time. In this preliminary study, ammonia concentrations in dogs without primary liver disease did not increase above the reference range after transfusion with pRBC.  相似文献   

19.
AIMS: To study the increase in phylloerythrin concentration in plasma and the disposition of phylloerythrin in skin and other tissues of sheep in which the hepatogenous photosensitisation,facial eczema, had been experimentally induced by dosing with the mycotoxin, sporidesmin. Spectroscopic differences between plasma and skin measurements of animals kept inside and outside after dosing were also studied in order to establish whether phylloerythrin undergoes photodegradation when exposed to sunlight. METHODS: Twenty-six Romney x Polled Dorset (25-30 kg)weaned female lambs were purchased from a commercial flock in the Waikato region, New Zealand. Twenty-two of these lambs were dosed with 0.25 mg sporidesmin/kg liveweight on each of two consecutive days (Days -1 and 0); the remaining four lambs served as controls. Both sporidesmin-dosed lambs and controls were randomly divided into two penned groups, one group housed inside in a darkened room and the others outside, exposed to natural sunlight. The lambs were fed green lucerne pellets and lucerne chaff ad libitum for 10 days prior to dosing and until Day 12 after the first dose; thereafter, all the lambs were fed fresh, cut grass (mainly ryegrass) ad libitum, until the end of the experimental period on Day 26. Plasma samples collected on Days -2, 7, 10, 12, 14, 17, 20 and 25were analysed for gamma glutamyltransferase (GGT) activity, bilirubin concentration, and the fluorescence spectrum of phylloerythrin. Spectrofluorometric analysis of phylloerythrin in skin was performed in vivo on the same days, using an external fiber-optic probe. RESULTS: Eight of 11 lambs (73%) kept outside after sporidesmin dosing became photosensitised during the experimental period. None of the sporidesmin-dosed animals kept inside showed clinical signs of photosensitisation. The GGT activity in plasma increased exponentially during the experimental period in all sporidesmin-dosed animals until it reached a plateau. All plasma obtained from sporidesmin-dosed sheep had spectral characteristics similar to those of phylloerythrin, namely a peak in the excitation spectrum at 422 nm and strong emission band at 650 (SE 1) and 709 (SE 1) nm. The fluorescence under excitation at 422 nm of phylloerythrin added to plasma from control lambs had identical peaks. Emission spectra obtained from plasma from healthy sheep without addition of phylloerythrin showed either no fluorescence or minor fluorescence at around 671 nm. Fluorescence in skin of sporidesmin-dosed animals had similar spectra to that in plasma. The appearance of the phylloerythrin-like spectra occurred 2-3 days later in the skin than in plasma, and phylloerythrin in sunlight-exposed skin did not suffer photodegradation during the course of the study. CONCLUSION: Plasma concentrations of phylloerythrin in healthy sheep were <0.1 micromol/l, and clinical signs of photosensitisation were not evident until concentrations exceeded 0.3 micromol/l. Plasma concentrations of phylloerythrin rose as high as 4.9 micromol/l in some animals. The concentration of phylloerythrin in skin began increasing 2-3 days later than that in blood. Hepatogenous photosensitisation can be diagnosed by analysis of plasma phylloerythrin concentrations using a spectroscopic method.  相似文献   

20.
The efficacy of estradiol cypionate (ECP) for synchronizing ovarian follicular development was determined in lactating Holstein-Friesian cattle. In Experiment 1, 13 cattle were given simultaneous intramuscular (i.m.) injections of 100 mg progesterone and 0 (control), 0.5 or 1.0 mg ECP on Day 3, after a synchronized ovulation (Day 0). Maximum diameter of the dominant follicle of Wave 1 was significantly larger in control cattle than in those given 0.5 or 1.0 mg ECP (means: 15.7, 13.2, and 12.9 mm, respectively). Mean day of emergence of Wave 2 was significantly later in controls than in those given 1.0 mg ECP, with the 0.5 mg group intermediate (Days 10.2, 8.8 and 9.5, respectively). In Experiment 2, 14 cattle were given a CIDR-B and IM injections of 1 mg ECP and 50 mg progesterone without regard to stage of cycle (treatment = Day 0). On Day 8, the CIDR-B was removed and 500 micrograms cloprostenol injected, IM. Mean days of wave emergence (Day 3.4; range: -2 to 7) and ovulation (Day 12.1; range: 10 to 14) indicated that ECP had limited efficacy for synchronizing follicular development and ovulation in dairy cattle when given at random stages of the estrous cycle.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号